EQL-101

EQL-101
Clinical data
Other namesEQL101
Drug classNon-hallucinogenic and non-cardiotoxic ibogaine analogue

EQL-101 is a non-hallucinogenic ibogaine analogue which is under development for the treatment of substance use disorders such as opioid use disorder.[1][2][3][4][5] It is said to preserve the therapeutic activity of ibogaine but to lack its hallucinogenic effects as well as certain adverse effects like cardiotoxicity.[1][3][4] The drug is under development by Equulus Therapeutics.[1][2][3][4][5] As of 2025, it is in the discovery or preclinical research stage of development.[5]

See also

References

  1. ^ a b c Shah-Neville W (17 April 2024). "Small but mighty: The role of small-molecule drugs in disease treatment". Labiotech.eu. Retrieved 26 January 2026. For example, Discordia's own company, EQUULUS, is developing small-molecule drugs for psychiatric and neurological disorders with a strong focus on addiction disorders. The company's lead asset, EQL-101, is a psychedelic-inspired anti-addiction therapeutic that is based on the therapeutic benefits of ibogaine. This is a naturally-occurring substance from the Iboga tree that has been used for many years to treat substance use disorders but has a significant and long hallucinogenic phase with dangerous and potentially lethal cardiac side effects. "EQL-101 is non-hallucinogenic and non-cardiotoxic but has been shown in preclinical testing to hold similar efficacy to treat addictions to various substances," said Discordia.
  2. ^ a b Alpha P (25 April 2024). "Pα+ Psychedelic Bulletin #162: EQUULUS Therapeutics Emerges from Stealth; Responses to ICER's Draft Evidence Report on Lykos' MDMA; and more…". Psychedelic Alpha. Retrieved 26 January 2026.
  3. ^ a b c Roberts M (10 October 2025). "After the Billion-Dollar Psychedelic Bet: Who's Next for Big Pharma?". Microdose. Retrieved 26 January 2026. A non-hallucinogenic ibogaine analog (EQL-101) — targeting addiction and depression with ibogaine's regenerative neurochemistry but none of its cardiac risk.
  4. ^ a b c Roberts M (6 May 2024). "Innovating CNS Disorder Treatment: EQUULUS and the Revolutionary Approach with Analog Ibogaine". Microdose. Retrieved 26 January 2026.
  5. ^ a b c "Psychedelics Drug Development Tracker". Psychedelic Alpha. Retrieved 26 January 2026.
Stub icon

This hallucinogen-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.